Table 1.

Demographic data.

Median age (range; y)	44 (19–82)
Male gender	47% (50)
Soft tissue sarcomas	74.5% (79)
Bone sarcomas	25.5% (27)
Molecular testing	89% (94)
Median prior lines of therapy	2.0 (0–8)
Median # of Phase 1 trials	1.0 (1–6)